Market research
3M4.F Masimo Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- P/E ratio
- 44.41
- Analyst target
- 298.8
- Dividend yield
- Not available
- Beta
- 1.1
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US5747951003
- P/E ratio
- 44.41
- Analyst target
- 298.8
- Dividend yield
- Not available
- Beta
- 1.1
About
About Masimo Corporation
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California. As of June 10, 2026, Masimo Corporation operates as a subsidiary of Danaher Corporation.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 3M4.F discussion.
5 years, 5 months ago
Masimo Corporation is currently in a long term uptrend where the price is trading 8.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.8.
Masimo Corporation's total revenue rose by 19.2% to $295M since the same quarter in the previous year.
Its net income has increased by 33.5% to $71M since the same quarter in the previous year.
Finally, its free cash flow fell by 11.5% to $50M since the same quarter in the previous year.
Based on the above factors, Masimo Corporation gets an overall score of 4/5.